genu
ebolaviru
compos
five
virus
zair
ebolaviru
ebov
sudan
ebolaviru
bundibugyo
ebolaviru
tai
forest
ebolaviru
reston
ebolaviru
reston
pathogen
human
endem
africa
genu
one
two
extant
genera
compos
famili
filovirida
marburgviru
ebola
viru
diseas
evd
human
difficult
diagnos
result
initi
nonspecif
symptom
common
number
infecti
agent
endem
africa
symptom
ultim
progress
sever
hemorrhag
fever
case
fatal
rate
rang
histor
ebov
caus
sporad
outbreak
central
africa
howev
epidem
western
africa
demonstr
potenti
viral
spread
region
africa
recent
smaller
persist
ebov
outbreak
ongo
democrat
republ
congo
highlight
continu
reemerg
pathogen
target
therapeut
come
market
littl
support
care
current
avail
patient
viru
entri
target
antivir
develop
filovirus
enter
suscept
cell
interact
sever
differ
cell
surfac
receptor
mediat
virion
attach
intern
endosom
compart
two
differ
group
cell
surfac
receptor
known
mediat
filoviru
uptak
phosphatidylserin
ps
receptor
tim
tam
famili
protein
ctype
lectin
receptor
clr
bind
glycan
heavili
glycosyl
viral
glycoprotein
gp
date
five
differ
ps
receptor
five
clr
shown
facilit
filovirion
uptak
bind
receptor
mediat
uptak
virion
endosom
filoviru
gp
proteolyt
process
cleav
gp
interact
cognat
receptor
within
late
endosomallysosom
compart
bind
requir
filoviru
entri
studi
suggest
least
one
addit
step
requir
trigger
membran
fusion
event
given
redund
attachmentintern
receptor
ubiquit
express
endosom
proteas
surpris
wide
rang
host
cell
suscept
infect
includ
macrophag
macrophag
known
play
critic
role
ebov
pathogenesi
cell
one
initi
cell
type
infect
ebov
target
throughout
cours
infect
facilit
system
dissemin
viru
infect
macrophag
result
aberr
product
proinflammatori
cytokin
synthesi
secret
vasoact
peptid
disrupt
vascular
permeabl
recruit
addit
suscept
cell
site
infect
creat
posit
feedback
loop
allow
viral
replic
system
spread
howev
macrophag
phenotyp
homogen
rather
adopt
broad
spectrum
phenotyp
depend
microenviron
includ
cytokin
expos
remark
phenotyp
plastic
respons
cytokin
stimuli
refer
macrophag
polar
classic
activ
macrophag
elicit
exposur
proinflammatori
signal
interferon
gamma
altern
activ
macrophag
immunomodulatori
macrophag
elicit
signal
cytokin
well
addit
immunosuppress
chemic
glucocorticoid
combin
treatment
immun
complex
ic
bacteri
lp
importantli
cell
perform
dispar
function
bodi
macrophag
upregul
express
number
proinflammatori
gene
subunit
tnf
mediat
clearanc
pathogen
macrophag
produc
number
immunomodulatori
compound
promot
resolut
inflamm
wound
heal
recent
becom
clear
classif
insuffici
describ
uniqu
specif
express
profil
induc
dispar
antiinflammatori
stimuli
result
field
move
toward
subdivid
macrophag
popul
frequent
refer
polar
specif
stimulu
administ
elicit
uniqu
characterist
macrophag
phenotyp
thu
treatment
refer
polar
wherea
iclp
dexamethason
treatment
frequent
refer
polar
respect
grow
bodi
research
indic
macrophag
polar
may
occur
variou
diseas
state
may
profoundli
impact
outcom
host
immun
respons
macrophag
popul
skew
toward
either
phenotyp
mani
chronic
diseas
state
diabet
atherosclerosi
cancer
cytokin
drive
macrophag
polar
state
influenc
outcom
infect
divers
pathogen
influenza
viru
salmonella
spp
brucella
leishmania
spp
other
given
critic
role
cell
cours
filoviru
infect
polar
statu
macrophag
might
well
influenc
ebov
infect
studi
lab
demonstr
treatment
result
polar
human
mous
macrophag
inhibit
ebov
infect
vivo
administ
late
hour
follow
ebov
challeng
abrog
morbid
mortal
find
provid
evid
elicit
proinflammatori
state
earli
time
filoviru
infect
control
filoviru
replic
howev
tissu
macrophag
mani
west
central
african
individu
may
manifest
strong
proinflammatori
phenotyp
earli
filoviru
infect
due
infect
exampl
helminth
infect
common
region
induc
system
respons
push
immun
respons
toward
antiinflammatori
phenotyp
evid
filoviru
infect
directli
push
macrophag
toward
state
known
filovirus
encod
antagonist
would
predict
block
effect
polar
thu
import
understand
effect
macrophag
polar
filoviru
infect
investig
effect
immunomodulatori
cytokin
ebov
infect
macrophag
limit
suggest
polar
macrophag
enhanc
filoviru
infect
matur
monocyt
macrophag
enhanc
ebola
viru
like
particl
ebov
vlp
entri
viru
entri
increas
modestli
stimuli
suggest
cytokin
polar
alter
suscept
cell
ebov
also
stimulu
exacerb
ebov
infect
knockout
mice
reduc
ebov
load
organ
late
time
infect
better
surviv
wildtyp
mice
studi
support
hypothesi
antiinflammatori
agent
may
enhanc
ebov
infect
howev
mechan
mediat
enhanc
yet
establish
show
polar
murin
periton
macrophag
enhanc
ebov
gpdepend
infect
increas
cell
surfac
express
clr
studi
primarili
use
recombin
vsv
encod
ebov
gp
rvsvebov
gp
costeffect
safe
surrog
model
ebov
infect
recombin
viru
use
numer
group
studi
filoviru
entri
offer
distinct
advantag
allow
filoviru
entri
studi
perform
outsid
laboratori
administr
macrophag
significantli
enhanc
ebov
gpdepend
viral
particl
bind
intern
increas
overal
infect
also
increas
surfac
express
sever
ctype
lectin
receptor
clr
human
monocyt
deriv
macrophag
murin
periton
macrophag
includ
dcsign
human
macrophag
mous
macrophag
enhanc
infect
block
mannan
indic
mannosebind
clr
dcsign
respons
increas
viru
infect
ectop
express
receptor
poorli
permiss
cell
increas
rvsvebov
gp
entri
relat
clr
administ
mice
prior
rvsvebov
gp
challeng
increas
virusassoci
mortal
transfer
ex
vivo
periton
macrophag
mice
enhanc
rvsvebov
gp
pathogenesi
total
studi
demonstr
polar
macrophag
gener
macrophag
highli
suscept
ebov
entri
infect
enhanc
cell
surfac
clr
highlight
import
macrophag
pathogenesi
ebov
studi
conduct
strict
accord
anim
welfar
act
recommend
guid
care
use
laboratori
anim
nation
institut
health
univers
iowa
ui
institut
assur
number
anim
procedur
approv
ui
institut
anim
care
use
committe
iacuc
overse
administr
iacuc
protocol
studi
perform
accord
iacuc
guidelin
protocol
filoviru
glycoproteincellular
protein
interact
receptordefici
ifnar
mice
kind
gift
dr
john
harti
univers
iowa
mice
kind
gift
dr
vijay
kuchroo
brigham
women
hospit
harvard
institut
medicin
mice
bred
breed
coloni
ifnar
mice
cross
creat
heterozyg
progeni
progeni
gener
interbr
mice
screen
correct
doubl
knockout
genotyp
expect
genotyp
produc
normal
mendelian
ratio
genom
dna
mous
tail
clip
assess
pcr
genotyp
genotyp
primer
previous
describ
util
pcr
amplif
cycl
sec
sec
mice
maintain
accord
iacuc
guidelin
univers
iowa
infect
perform
use
viru
provid
predict
kill
mice
determin
stock
viru
prepar
highli
depend
sex
mous
dose
use
individu
experi
chosen
best
address
experiment
question
ask
infect
perform
intraperiton
inject
mice
monitor
daili
sign
morbid
mice
euthan
accord
defin
iacuc
protocol
harvest
organ
mice
anesthet
isofluran
perfus
left
ventricl
pb
flush
vasculatur
organ
harvest
weigh
snap
frozen
liquid
nitrogen
rna
isol
whole
organ
use
trizol
previous
describ
ex
vivo
experi
periton
macrophag
isol
polar
describ
follow
polar
cell
wash
vigor
pb
lift
versen
wash
steril
pb
remov
residu
mediadissoci
reagent
adopt
transfer
subsequ
perform
inject
pmac
recipi
mous
infect
hour
follow
later
resid
periton
macrophag
obtain
mice
periton
lavag
rpmi
penstrep
cell
wash
pb
resuspend
rpmi
contain
fb
penstrep
nonessenti
amino
acid
neaa
sodium
pyruv
murin
mcsf
hour
cell
wash
pb
remov
nonadher
cell
gener
macrophag
enrich
popul
cell
compos
greater
macrophag
bone
marrow
deriv
macrophag
obtain
bone
marrow
precursor
isol
femur
adult
mice
cell
obtain
flush
lumen
femur
rpmi
contain
fb
penstrep
cell
pass
cell
strainer
wash
pb
plate
isol
media
contain
murin
mcsf
promot
differenti
macrophag
cell
readi
use
follow
day
differenti
human
macrophag
matur
monocyt
obtain
leukocyt
reduct
cone
contain
enrich
peripher
leukocyt
healthi
donor
degowin
blood
center
univers
iowa
hospit
clinic
mononuclear
cell
purifi
ficol
gradient
monocyt
select
adher
tissu
cultur
flask
coat
gelatin
pretreat
human
plasma
follow
isol
monocyt
plate
rpmi
fb
penstrep
human
serum
human
mcsf
cell
matur
day
point
wash
pb
remov
nonadher
cell
cell
polar
human
cytokin
day
differenti
polar
macrophag
cultur
achiev
incub
cell
h
plate
media
without
mcsf
hour
follow
polar
media
remov
replac
plate
medium
without
cytokin
harvest
rna
infect
viru
rna
isol
use
trizol
reagent
invitrogen
step
perform
accord
manufactur
specif
rna
subsequ
convert
cdna
high
capac
cdna
revtran
kit
appli
biosystem
total
rna
use
input
reaction
quantit
pcr
perform
use
power
sybr
green
master
mix
appli
biosystem
accord
manufactur
instruct
util
real
time
pcr
machin
appli
biosystem
cdna
use
well
primer
use
follow
hprt
forward
hprt
revers
vsvm
forward
vsvm
revers
gapdh
forward
gapdh
revers
dcsign
forward
dcsign
revers
mgl
forward
mgl
revers
forward
revers
forward
revers
forward
revers
forward
ttt
tag
ggt
tac
ggc
cgg
revers
cct
cga
ggc
tgt
cct
ttt
forward
aag
ctc
tcc
aga
agc
aat
revers
tag
gaa
gat
ccc
agc
tgt
forward
ccc
agg
aag
agg
ctg
ata
revers
tct
acg
gtg
gtg
gtt
cat
forward
gct
caa
caa
ttt
cga
caa
ggt
revers
ggg
cta
aag
tct
tgg
ttg
forward
tgc
cac
aga
agg
cgg
tac
revers
ttg
tga
aca
tgc
gcc
tca
mertk
forward
mertk
revers
forward
revers
axl
forward
axl
revers
forward
revers
forward
revers
integrin
alpha
forward
integrin
alpha
revers
forward
revers
forward
revers
forward
revers
forward
revers
forward
revers
surfac
stain
perform
presenc
fc
receptor
blocker
monoclon
antibodi
bioxcel
follow
antibodi
use
detect
clec
surfac
cell
antimurin
clone
invitrogen
antimurin
clone
ebiosci
antimurin
catalog
number
r
system
antihuman
dcsign
clone
santa
cruz
biotechnolog
antimurin
catalog
number
r
system
antimurin
catalog
number
r
system
antimurin
catalog
number
r
system
cell
stain
fac
tube
dark
ice
minut
addit
stain
requir
secondari
antibodi
two
wash
pb
fb
perform
stain
reduc
background
cell
run
either
bd
facscalibur
bd
facsvers
flow
cytomet
fluoresc
quantifi
percent
posit
cell
use
flowjo
treestar
recombin
vesicular
stomat
viru
express
glycoprotein
ebov
mayinga
vsv
g
gener
previous
describ
viru
propag
infect
vero
cell
low
moi
collect
supernat
result
supernat
filter
filter
purifi
ultracentrifug
hr
sucros
cushion
result
stock
resuspend
small
volum
pb
frozen
use
stock
use
vivo
studi
purifi
treatment
endotoxin
remov
kit
detoxigel
endotoxin
remov
gel
thermofish
scientif
aliquot
store
use
viral
titer
determin
assay
vero
cell
import
note
multipl
viru
stock
use
cours
experi
relationship
stock
uniqu
stock
stock
lowest
dose
viru
provid
consist
lethal
determin
amount
viru
experi
determin
whether
subleth
lethal
dose
virus
requir
studi
recombin
virus
rvsvebov
gp
rvsvg
assess
abil
infect
cytokin
treat
untreat
primari
human
mous
macrophag
well
transient
transfect
hek
cell
studi
infect
assess
two
method
virus
encod
gfp
genom
infect
assess
studi
number
gfp
cell
infect
well
hour
follow
infect
assay
cell
infect
quantiti
viru
achiev
gfp
posit
unstimul
cultur
level
viru
infect
linear
rang
infect
curv
allow
detect
subtl
increas
decreas
viral
infect
approxim
moi
use
studi
note
figur
legend
viru
infect
also
assess
viral
load
determin
via
qrtpcr
analysi
use
primer
condit
describ
hek
cell
seed
tissu
cultur
plate
dmem
fb
ps
cell
cotransfect
use
optim
pei
protocol
four
separ
plasmid
np
contain
ebov
gp
ratio
respect
approxim
sixteen
hour
posttransfect
media
plate
replac
fresh
media
supernat
collect
hour
supernat
filter
pvdf
syring
filter
unit
celltreat
cat
vlp
concentr
overnight
rpm
viru
purifi
ultracentrifug
rpm
sucros
cushion
sw
rotor
purifi
viral
particl
thoroughli
resuspend
pb
aliquot
determin
approxim
concentr
vlp
protein
concentr
determin
use
bsa
standard
vlp
analyz
western
blot
stain
gp
ibt
bioservic
gp
cat
cat
respect
gp
signal
compar
serial
dilut
purifi
aliquot
solubl
gp
sino
biolog
transfect
hek
cell
perform
use
reagent
polyethylenimin
stock
transfect
dish
plasmid
dna
nacl
combin
pei
nacl
mixtur
incub
room
temperatur
minut
ad
dropwis
cell
hour
follow
transfect
cell
wash
pb
replat
well
dish
dmem
fb
hour
replat
cell
readi
use
protein
express
found
peak
hour
post
transfect
mannan
nacetylgalactosamin
galnac
obtain
powder
fisher
scientif
resuspend
concentr
steril
pb
competit
inhibit
viru
bind
perform
incub
target
cell
inhibitor
final
concentr
one
hour
subsequ
infect
continu
presenc
inhibitor
ps
sigma
liposom
gener
dissolv
chloroform
dri
resuspend
pb
sonic
minut
ice
previous
describ
ps
liposom
ad
cell
concentr
one
hour
prior
addit
viru
allow
competit
bind
occur
previous
shown
bind
assay
perform
place
cell
ice
ad
rvsvebov
gp
moi
hour
allow
bind
intern
cell
subsequ
wash
twice
pb
remov
unbound
viru
viru
bound
cell
lyse
trizol
rna
isol
convert
cdna
viral
cdna
detect
quantit
pcr
entri
assay
perform
util
ebov
vlp
contain
describ
assay
perform
describ
tschern
garciasastr
briefli
cell
incub
optimem
ebov
vlp
approxim
protein
per
well
hour
ice
allow
bind
cell
wash
resuspend
media
shift
hour
cell
wash
lift
trypsin
move
fac
tube
cell
resuspend
optimem
contain
liveblaz
fret
reagent
prepar
accord
manufactur
guidelin
invitrogen
substrat
prepar
accord
manufactur
guidelin
cell
subsequ
wash
evalu
fluoresc
pacif
blue
channel
bd
facsvers
quantifi
substrat
cleavag
vitro
experi
shown
mean
error
express
standard
deviat
signific
determin
two
tail
student
ttest
alpha
vivo
experi
signific
determin
use
logrank
mantelcox
test
statist
calcul
use
graphpad
prism
softwar
graphpad
softwar
inc
evalu
role
macrophag
polar
ebov
infect
util
rvsvebov
gp
viru
excel
model
studi
ebov
entri
event
sinc
rvsv
strongli
inhibit
type
interferon
murin
monocyt
macrophag
obtain
interferon
receptor
ifnar
mice
howev
key
vitro
experi
also
perform
use
wt
murin
cell
human
monocyt
deriv
macrophag
mdm
intact
type
interferon
signal
use
cell
sought
determin
effect
polar
viru
infect
polar
shown
play
clear
role
diseas
state
like
relev
varieti
helminthinfect
african
patient
popul
expos
ebov
focus
effect
polar
rvsvebov
gp
infect
larg
number
studi
use
elicit
phenotyp
macrophag
verifi
primari
cell
interest
murin
resid
periton
macrophag
pmac
chang
gene
express
occur
reflect
function
macrophag
polar
follow
treatment
found
chang
consist
report
other
allow
us
confid
util
cytokin
induc
phenotyp
fig
next
investig
effect
cytokin
abil
murin
pmac
human
mdm
support
infect
rvsvebov
gp
found
macrophag
robustli
infect
rvsvebov
gp
compar
nonpolar
control
increas
infect
observ
fig
contrast
infect
rvsvg
express
nativ
vsv
g
glycoprotein
enhanc
stimul
suggest
increas
infect
specif
ebov
glycoproteinexpress
viru
verifi
effect
observ
murin
pmac
impact
lack
type
interferon
signal
perform
similar
experi
wt
pmac
found
treatment
increas
infect
consist
effect
observ
ifnar
cell
fig
find
suggest
treatment
enhanc
rvsvebov
gp
infect
ebov
gpdepend
manner
evalu
earliest
step
infect
bind
entri
pmac
human
mdm
pretreat
hour
rvsvebov
gp
bound
cell
prevent
virion
intern
unbound
viru
remov
total
rna
isol
quantiti
viru
bound
cell
assess
qrtpcr
amplif
viral
genom
virion
bear
ebov
gp
bound
macrophag
effici
nonpolar
macrophag
fig
suggest
polar
enhanc
surfac
express
viral
adhes
factorsreceptor
determin
virion
fusion
event
also
enhanc
macrophag
ebov
viru
like
particl
vlp
contain
ebov
fuse
assess
fusion
effici
ebov
vlp
fusion
event
measur
cell
load
fluoresc
contain
dye
flow
cytometri
describ
other
pmac
expos
suscept
vlp
fusion
fig
demonstr
enhanc
entri
like
secondari
enhanc
bind
least
part
respons
increas
infect
observ
macrophag
importantli
vlp
express
nativ
vsv
glycoprotein
exhibit
increas
fusion
treat
pmac
provid
strong
evid
increas
entri
pmac
specif
ebov
gp
fig
enhanc
virion
bind
entri
cell
suggest
one
cell
surfac
receptor
use
filovirus
upregul
evalu
express
gene
encod
mani
known
cell
surfac
receptor
use
ebov
assess
qrtpcr
untreat
pmac
express
clr
macrophag
galactos
bind
lectin
mgl
upregul
treatment
fig
addit
two
ps
receptor
critic
endosom
receptor
modestli
enhanc
express
known
filoviru
surfac
receptor
unchang
express
modestli
increas
presenc
incub
stimul
unstimul
pmac
presenc
liposom
compos
phosphatidylserin
ps
liposom
competit
inhibit
psdepend
attach
ebov
ps
receptor
therebi
block
psdepend
entri
found
enhanc
viru
infect
pmac
regardless
whether
ps
liposom
present
suggest
receptor
mediat
infect
fig
also
investig
upregul
dcsign
human
mdm
well
murin
ortholog
pmac
treatment
previous
shown
upregul
express
dcsign
human
dendrit
cell
consist
report
found
human
mdm
express
significantli
higher
amount
dcsign
rna
number
mdm
express
dcsign
cell
surfac
increas
stimul
fig
mice
encod
potenti
dcsign
ortholog
report
differ
whether
function
similar
human
dcsign
found
treatment
dramat
enhanc
rna
express
pmac
fig
suggest
andor
similar
dcsign
respons
addit
number
cell
within
pmac
popul
express
cell
surfac
clr
mgl
enhanc
cytokin
treatment
howev
neither
ps
receptor
increas
fig
parallel
surfac
stain
studi
unabl
detect
express
data
suggest
clr
may
respons
enhanc
ebov
gpdepend
entri
treat
pmac
evalu
murin
signr
famili
member
capabl
enhanc
rvsvebov
gp
infect
transfect
express
plasmid
dcsign
hek
cell
lack
known
ebov
surfac
receptor
poorli
permiss
infect
transfect
human
dcsign
use
posit
control
result
enhanc
rvsvebov
gp
infect
fig
interestingli
transient
express
increas
ebov
infect
albeit
lower
level
dcsign
wherea
express
increas
infect
less
twofold
importantli
none
receptor
express
hek
cell
impact
rvsvg
infect
degre
seen
rvsvebov
gp
although
dcsign
achiev
statist
signific
fig
demonstr
express
human
dcsign
murin
mgl
increas
macrophag
assess
effect
receptor
viru
infect
use
carbohydratebas
competitor
hek
cell
transfect
dcsign
mgl
infect
rvsvebov
gp
presenc
absenc
mannan
nacetyl
galactosamin
galnac
bind
dcsign
mgl
respect
addit
mannan
galnac
reduc
infect
dcsign
transfect
cell
wherea
galnac
block
mgl
depend
infect
fig
mannan
galnac
specif
reduc
viru
infect
polar
murin
pmac
human
mdm
fig
indic
mannos
bind
receptor
respons
mediat
viru
uptak
result
conjunct
earlier
qrtpcr
data
strongli
suggest
upregul
mediat
increas
rvsvebov
gp
suscept
polar
murin
macrophag
find
indic
murin
pmac
act
manner
similar
dcsign
hmdm
regard
ebov
infect
impact
upregul
mannosebind
clr
viru
infect
pmac
statist
signific
modest
effect
postul
one
possibl
explan
limit
enhanc
viru
infect
pmac
receptor
util
ebov
also
avail
util
pmac
thu
investig
use
anoth
sourc
primari
macrophag
bone
marrow
found
bone
marrow
deriv
mcsf
matur
macrophag
bmdm
poorli
support
rvsvebov
gp
infect
stimul
upregul
express
enhanc
infect
fig
henc
return
use
pmac
murin
pmac
express
upon
treatment
constitut
express
ps
receptor
shown
serv
filoviru
receptor
hek
cell
investig
constitut
high
level
express
mediat
filoviru
entri
pmac
make
viru
uptak
redund
therebi
reduc
impact
express
filoviru
infect
test
evalu
express
observ
strong
express
pmac
express
bmdm
fig
also
observ
pmac
mice
support
higher
level
viral
infect
mice
wherea
differ
suscept
wildtyp
versu
bmdm
fig
vlp
fusion
event
also
significantli
decreas
pmac
mice
compar
pmac
fig
show
import
receptor
ebov
pmac
observ
explain
poor
suscept
bmdm
previous
observ
fig
howev
express
enhanc
treatment
fig
receptor
respons
increas
viru
infect
mediat
reason
infect
mediat
obscur
subtler
effect
treatment
effect
would
like
profound
pmac
inde
pmac
mice
sensit
effect
polar
increas
infect
observ
polar
cell
effect
observ
rvsvebov
gp
rvsvg
fig
addit
rvsvebov
gp
bind
vlp
membran
fusion
strongli
enhanc
pmac
polar
stronger
effect
bind
previous
observ
fig
mannan
galnac
inhibit
enhanc
pmac
provid
evid
mannos
bind
clr
respons
cytokinedepend
increas
infect
fig
assess
role
macrophag
polar
rvsvebov
infect
vivo
challeng
control
ifnar
mice
viru
howev
initi
need
determin
vivo
treatment
would
polar
pmac
administ
polar
stimulu
ip
parallel
polar
stimulu
also
test
effect
hour
periton
cell
consist
primarili
macrophag
also
contain
epitheli
cell
cell
type
isol
chang
gene
express
qrtpcr
assess
found
express
marker
gene
modestli
increas
mice
administ
marker
gene
particular
increas
treat
mice
fig
data
suggest
acut
vivo
polar
resid
periton
macrophag
occur
follow
administr
singl
dose
polar
stimuli
provid
valid
vivo
cytokin
polar
studi
determin
enhanc
rvsvebov
gp
infect
vivo
ifnar
mice
administ
either
pb
ip
h
later
infect
ip
subleth
dose
rvsvebov
mice
monitor
daili
surviv
found
vivo
polar
mice
elicit
modestli
enhanc
mortal
fig
wherea
rvsvg
challeng
equal
virul
pb
treat
mice
fig
evalu
role
periton
macrophag
vivo
phenotyp
pmac
harvest
mice
day
post
infect
viral
load
assess
qrtpcr
found
enhanc
vivo
infect
pmac
upon
rvsvebov
gp
challeng
rvsvg
fig
data
suggest
vivo
administr
increas
viru
load
ebov
gpdepend
manner
parallel
mice
challeng
anticip
mice
would
even
sensit
effect
treatment
studi
higher
concentr
rvsvebov
gp
administ
sinc
observ
mice
decidedli
less
permiss
viru
observ
loss
protect
mice
viru
challeng
fig
mice
dose
rvsvebov
gp
result
mortal
pbstreat
mice
caus
mortal
mice
fig
recogn
vivo
administr
larg
bolu
cytokin
like
addit
effect
immun
respons
perform
ex
vivo
polar
adopt
transfer
treat
macrophag
prior
challeng
mice
rvsvebov
gp
observ
vivo
polar
mice
increas
mortal
fig
compar
mice
receiv
pbstreat
macrophag
although
adopt
transfer
may
increas
sensit
mice
viru
sinc
half
pbstreat
mice
also
succumb
viru
infect
condit
taken
togeth
data
provid
evid
polar
exacerb
ebov
infect
vivo
like
due
enhanc
infect
critic
cell
popul
periton
macrophag
demonstr
studi
polar
increas
express
cell
surfac
receptor
import
ebov
infect
mous
pmac
human
mdm
result
enhanc
ebola
gpdepend
infect
wildtyp
ifnar
cell
vivo
administr
addit
pmac
mice
result
greater
viral
pathogenesi
reflect
increas
mortal
demonstr
vivo
vitro
enhanc
ebov
gp
specif
entri
rvsvg
infect
mice
pmac
alter
cytokin
propos
find
extend
wt
ebov
potenti
filovirus
mechan
entri
highli
conserv
import
highlight
use
model
viru
experi
rvsvebov
gp
found
excel
model
understand
ebov
entri
recapitul
step
bind
intern
howev
less
wellsuit
studi
filoviru
pathogenesi
postentri
event
dictat
vsv
genom
thu
vivo
studi
includ
rvsvg
control
enabl
us
demonstr
enhanc
pathogenesi
vivo
specif
viru
encod
ebov
gp
futur
experi
ebov
would
valuabl
extend
find
also
note
model
viru
necessit
use
ifnar
mice
surviv
studi
mani
tissu
cultur
studi
perform
ifnar
pmac
although
wt
pmac
human
mdm
evalu
well
found
respond
similar
manner
ifnar
cell
addit
lack
type
ifn
signal
ifnar
cell
modestli
alter
adapt
immun
respons
thu
use
mice
potenti
caveat
studi
show
polar
pmac
enhanc
viru
replic
pathogenesi
upregul
express
clr
cell
surfac
mannosebind
clr
dcsign
human
mice
increas
surfac
pmac
h
treatment
express
mgl
anoth
clr
support
ebov
bind
intern
also
significantli
upregul
treatment
howev
mannos
polym
mannan
abrog
enhanc
mgl
ligand
galnac
despit
similar
level
receptor
upregul
suggest
effici
receptor
macrophag
inher
disagre
report
mgl
mediat
entri
context
also
note
chang
potenti
receptor
includ
endosom
receptor
could
contribut
enhanc
entri
upon
exposur
howev
studi
mannan
suggest
mannosebind
clr
critic
effect
dcsign
previous
shown
receptor
attach
intern
ebov
receptor
vsv
howev
attempt
identifi
mous
ortholog
function
similar
dcsign
met
limit
success
baribaud
et
al
clone
murin
cdna
initi
propos
function
murin
ortholog
cdna
shown
ident
human
dcsign
bound
manner
similar
human
dcsign
howev
author
note
express
cdna
result
effici
transmiss
hiv
cell
mix
cultur
suggest
receptor
entir
recapitul
behavior
human
dcsign
murin
cdna
shown
other
encod
murin
murin
clr
cire
also
evalu
murin
homolog
human
dcsign
howev
found
bind
ebov
gp
author
conclud
mice
dcsign
homolog
serv
cell
surfac
receptor
ebov
find
abl
mediat
viru
entri
wherea
less
effect
receptor
find
consist
work
gramberg
et
al
well
previou
studi
found
bind
mannos
complex
mannos
contain
glycan
manner
similar
dcsign
possess
endocyt
capabl
wherea
lack
crucial
endocyt
function
mediat
rvsvebov
gp
infect
upregul
expos
addit
evid
also
show
exposur
increas
express
bmdm
polar
macrophag
exhibit
enhanc
rvsvebov
gp
infect
total
data
provid
strong
evid
upregul
key
compon
increas
viru
infect
murin
macrophag
thu
propos
murin
function
similar
manner
human
dcsign
context
ebov
infect
polar
role
previous
recogn
structur
basi
somewhat
unexpect
murin
mediat
ebov
bind
intern
amino
acid
extracellular
neck
domain
dcsign
compos
repeat
thought
import
oligomer
receptor
facilit
high
affin
bind
carbohydr
ligand
similar
long
repeat
domain
absent
murin
protein
neck
domain
shorter
contain
residu
respect
howev
appar
neck
domain
suffici
homooligomer
shown
weakli
form
dimer
upon
ligand
interact
ad
structur
issu
clr
amino
acid
motif
compos
dcsign
carbohydr
bind
domain
complet
conserv
potenti
result
reduc
glycan
bind
studi
provid
evid
import
macrophag
ebov
infect
previous
shown
macrophag
profoundli
resist
ebov
infect
mice
protect
ebov
adopt
transfer
murin
pmac
protect
mice
challeng
ip
otherwis
lethal
dose
rvsvebov
gp
roger
et
al
manuscript
review
show
macrophag
exert
opposit
effect
polar
exacerb
rvsvebov
gp
infect
vitro
vivo
find
indic
pmac
play
pivot
role
rvsvebov
gp
pathogenesi
like
ebov
pathogenesi
viru
administ
ip
exert
effect
far
exce
preval
bodi
futur
studi
need
investig
role
tissu
macrophag
viru
administ
via
rout
interest
understand
physiolog
patholog
condit
may
push
macrophag
popul
state
might
influenc
cours
filoviru
infect
diseas
state
elicit
strong
respons
may
skew
macrophag
phenotyp
although
mani
chronic
diseas
complex
appreci
elicit
mix
phenotyp
circumst
two
well
establish
diseas
state
elicit
phenotyp
parasit
infect
caus
roundworm
whipworm
tumor
worm
elicit
strong
type
immun
respons
may
play
import
role
preexist
condit
filoviru
outbreak
estim
billion
individu
worldwid
infect
parasit
worm
greatest
preval
subsaharan
africa
ebov
coendem
furthermor
estim
million
children
need
treatment
pathogen
highlight
preval
infect
difficulti
provid
care
given
find
cytokin
elicit
enhanc
viru
infect
macrophag
futur
studi
warrant
understand
role
helminth
infect
ebov
coinfect
may
profound
clinic
implic
macrophag
present
tumor
tam
also
express
antiinflammatori
phenotyp
thought
help
drive
tumorigenesi
studi
investig
whether
malign
drive
robust
filoviru
replic
loss
immun
control
combin
enhanc
presenc
polar
macrophag
found
tumorigenesi
would
anticip
establish
vivo
set
conduc
filoviru
infect
note
ebov
infect
may
alter
macrophag
polar
state
ebov
gp
interact
signal
howev
effect
interact
macrophag
polar
directli
examin
interact
gener
polar
state
combin
immun
complex
lp
stimul
state
thu
would
interest
examin
effect
ebov
gp
macrophag
gene
express
final
studi
also
highlight
import
ebov
gpdepend
entri
murin
pmac
previous
shown
ectop
express
human
mous
hek
cell
enhanc
rvsvebov
gp
entri
appreci
tissu
macrophag
dendrit
cell
popul
express
endogen
human
mice
role
receptor
filoviru
infect
primari
popul
previous
report
two
line
evid
indic
import
ebov
infect
pmac
first
infect
pmac
inhibit
addit
ps
liposom
second
viru
infect
pmac
markedli
lower
pmac
consist
import
role
receptor
pmac
mask
effect
polar
effect
notabl
enhanc
absent
total
studi
abl
teas
apart
multipl
layer
host
receptordepend
event
drive
filoviru
entri
infect
